The global frontotemporal dementia management industry demand is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.
Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management. These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia.
To Remain Ahead of Your Competitors, Request For A Sample! https://www.futuremarketinsights.com/reports/sample/rep-gb-16489
According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause for Frontotemporal dementia is still unknown it majorly affects the individual between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives, increase in the number of research partnerships, presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Frontotemporal Dementia Management market grew at a CAGR of 4%.
- The global Frontotemporal Dementia Management market is expected to grow with a 6% CAGR during 2023 to 2033.
- As of 2033, the Frontotemporal Dementia Management Market is expected to reach US$ 17.91 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 25% market share for the Frontotemporal Dementia Management market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Frontotemporal Dementia Management.” says an FMI analyst
Connect With Our Analyst To Address Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16489
Market Competition:
Key players in the Frontotemporal Dementia Management market are
- Pfizer Inc.
- Johnson & Johnson
- Sanofi S.A.
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Novartis AG
- Mylan N.V.
- Merck & Company, Inc.
- AstraZeneca plc.
- Allergen plc
Recent Development:
- In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
- Alzheimer’s Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.
Discover the Future of Marketing: Get Your Hands on Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16489
Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey:
Drug Class Type:
- Antidepressants
- Fluoxetine
- Fluvoxamine
- Sertraline
- Paroxetine
- Citalopram
- Bupropion
- Mirtazapine
- Antipsychotics
- Olanzapine
- Quetiapine
- Ziprasidone
- Aripiprazole
- Risperidone
- Paliperidone
End-Users:
- Hospitals
- Specialty clinics
- Others
Distribution Channel:
- Hospital Pharmacy
- Drug store
- Retail Pharmacy
- Online Pharmacy
- Others
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube